Scholarlink

<p>Getah virus (GETV), a mosquito-borne arbovirus, possesses many susceptible hosts, including pigs, horses, cattle, and blue foxes. Currently, the biological characteristics and pathogenic mechanisms of GETV remain to be investigated. A GETV, isolated from a contaminated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) live vaccine, was designated as BJ-Swzp-2022. Subsequently, the complete genome of the GETV BJ-Swzp-2022 was sequenced to construct a full-length infectious cDNA clone using T7 RNA polymerase. Transfection of BSR T7/5 cells expressing T7 RNA polymerase with this infectious clone resulted in the rescue of GETV, which exhibited replication and replication characteristics similar to those of the parental virus. Establishing this platform would facilitate understanding the pathogenic mechanisms of GETV and developing novel vaccines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Generation of an infectious cDNA clone of BJ-Swzp-2022, a Group III Isolate of Getah Virus

  • 期刊论文

  • 发表日期：

    2026年2月7日

查看全文
  • Dongni Kong,
  • Liang Meng,
  • Dan Liu,
  • Jia Wang,
  • Xiaojie Huang,
  • Tianshu Zhai,
  • Yong Deng,
  • Qi Xue,
  • Hongju Wu,
  • Yaqing Mao,
  • Haiwei Wang,
  • Huawei Wu

摘要

Getah virus (GETV), a mosquito-borne arbovirus, possesses many susceptible hosts, including pigs, horses, cattle, and blue foxes. Currently, the biological characteristics and pathogenic mechanisms of GETV remain to be investigated. A GETV, isolated from a contaminated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) live vaccine, was designated as BJ-Swzp-2022. Subsequently, the complete genome of the GETV BJ-Swzp-2022 was sequenced to construct a full-length infectious cDNA clone using T7 RNA polymerase. Transfection of BSR T7/5 cells expressing T7 RNA polymerase with this infectious clone resulted in the rescue of GETV, which exhibited replication and replication characteristics similar to those of the parental virus. Establishing this platform would facilitate understanding the pathogenic mechanisms of GETV and developing novel vaccines.